摘要
目的研究前列腺癌组织特异性长链非编码RNA(lncRNA)表达及其临床意义。方法利用生物信息学方法深入分析TCGA及GEO基因组数据库,对数据库收录的492例前列腺癌组织和152例癌旁组织做基因差异分析,筛选出差异表达的lncRNA,并进一步分析上述lncRNA的前列腺组织特异性及对前列腺癌患者预后的影响。结果筛选出差异表达的5个lncRNA包括:前列腺相关转录因子14(PCAT14)、前列腺抗原3(PCA3)、C末端结合蛋白1-AS(CTBP1-AS)、DRAIC、GPC5-AS1。其中,PCAT14、PCA3在前列腺癌组织中特异性表达,二者升高提示与前列腺癌预后相关,且二者与激肽释放酶相关肽酶3(KLK3)、α-甲基酰基辅酶A消旋酶(AMACR)、溶质转运蛋白家族45A3(SLC45A3)等前列腺癌特异抗原相关性好。针对PCAT14、PCA3进行GO功能富集分析和KEGG通路富集分析提示:PCA3差异表达与吞噬作用、细胞识别、对细菌的防御反应、免疫球蛋白复合物、高尔基体、抗原结合、趋化因子受体结合、蛋白质消化吸收、肾素-血管紧张素系统等信号通路等密切相关;PCAT14差异表达与高尔基体、离子通道的活动相关通路,同时与肾素分泌、环磷酸腺苷(cAMP)信号通路、促性腺激素分泌相关信号通路等密切相关。结论PCA3、PCAT14在前列腺癌组织中特异性表达,在正常组织中基本不表达,可以作为前列腺癌诊断的潜在指标。
Objective To explore the expression and clinical significance of prostate cancer tissue-specific lncRNAs.Methods The gene differences of 492 prostate cancer tissues and 152 adjacent tissues in TCGA and GEO genomic databases were analyzed with bioinformatics methods.A total of 5 lncRNAs were screened out,and their specificity in prostate tissues and impact on the prognosis of patients were analyzed.Results The 5 lncRNAs included PCAT14,PCA3,CTBP1-AS,DRAIC,and GPC5-AS1.PCAT14 and PCA3 were specifically expressed in prostate cancer tissues,and elevated expression was related to the prognosis.Moreover,they were well correlated with prostate cancer-specific antigens such as KLK3,AMACR,SLC45A3,and so on.GO function enrichment analysis and KEGG pathway enrichment analysis showed that the differential expression of PCA3 was closely related to phagocytosis,cell recognition,defense response to bacteria,immunoglobulin complex,Golgi apparatus,antigen binding,chemokine receptor binding,white matter digestion and absorption,renin-angiotensin system and other signaling pathways,while the differential expression of PCAT14 was closely related to the activity of Golgi apparatus and ion channels,renin secretion,cAMP signaling pathway,and gonadotropin secretion-related signaling pathway.Conclusion PCA3 and PCAT14 are specifically expressed in prostate cancer tissues,not in normal tissues,which can be used as potential indicators for the diagnosis of prostate cancer.
作者
陈平舟
许清江
林煌
黄翔
吴翔
CHEN Pingzhou;XU Qingjiang;LIN Huang;HUANG Xiang;WU Xiang(Department of Urology,Fujian Provincial Hospital,Fuzhou 350004;Department of Urology,Nanping First Hospital Affiliated to Fujian Medical University,Nanping 353000,China)
出处
《现代泌尿外科杂志》
CAS
2024年第3期232-237,267,共7页
Journal of Modern Urology
基金
福建省科技创新联合资金项目(No.2020Y9024)。
